4.7 Review

The Coming Age of Flavonoids in the Treatment of Diabetic Complications

期刊

JOURNAL OF CLINICAL MEDICINE
卷 9, 期 2, 页码 -

出版社

MDPI
DOI: 10.3390/jcm9020346

关键词

flavonoids; diabetes; microvascular complications; cardiovascular disease; diabetic nephropathy; oxidative stress; inflammation; therapeutics

资金

  1. FEDER-ISCIII Funds [PI17/00130, PI17/01495]
  2. Spanish Ministry of Economy and Competitiveness [RTI2018-098788-B-100, DTS17/00203, DTS19/00093, RYC-2017-22369]
  3. Spanish Society of Cardiology (SEC)
  4. Spanish Society of Nephrology (SEN)
  5. Spanish Society of Atherosclerosis (SEA)
  6. joint-RETOS Collaborations Project 2017 - Spanish Ministry of Economy and Competitiveness [RTC-2017-6089-1]

向作者/读者索取更多资源

Diabetes mellitus (DM), and its micro and macrovascular complications, is one of the biggest challenges for world public health. Despite overall improvement in prevention, diagnosis and treatment, its incidence is expected to continue increasing over the next years. Nowadays, finding therapies to prevent or retard the progression of diabetic complications remains an unmet need due to the complexity of mechanisms involved, which include inflammation, oxidative stress and angiogenesis, among others. Flavonoids are natural antioxidant compounds that have been shown to possess anti-diabetic properties. Moreover, increasing scientific evidence has demonstrated their potential anti-inflammatory and anti-oxidant effects. Consequently, the use of these compounds as anti-diabetic drugs has generated growing interest, as is reflected in the numerous in vitro and in vivo studies related to this field. Therefore, the aim of this review is to assess the recent pre-clinical and clinical research about the potential effect of flavonoids in the amelioration of diabetic complications. In brief, we provide updated information concerning the discrepancy between the numerous experimental studies supporting the efficacy of flavonoids on diabetic complications and the lack of appropriate and well-designed clinical trials. Due to the well-described beneficial effects on different mechanisms involved in diabetic complications, the excellent tolerability and low cost, future randomized controlled studies with compounds that have adequate bioavailability should be evaluated as add-on therapy on well-established anti-diabetic drugs.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据